[CAS NO. 68592-15-4] 4-O-Methyl honokiol
PRODUCTS SPECIFICATIONS [68592-15-4]
DESCRIPTION [68592-15-4]
Overview
| MDL | MFCD19705288 |
|---|---|
| Molecular Weight | 280.36 |
| Molecular Formula | C19H20O2 |
| SMILES | OC1=CC=C(CC=C)C=C1C2=CC=C(OC)C(CC=C)=C2 |
Summary
IC50 & Target
|
PPARγ |
NF-κB |
In Vitro
4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis , acts as a PPARγ agonist, and inhibtis NF-κB activity. 4-O-Methyl honokiol (20 μM) increases the expression, transcription and DNA binding activities, and nuclear translocation of PPARγ in both in prostate PC-3 and LNCap cells. 4-O-Methyl honokiol (0-30 μM) inhibits LNCaP and PC-3 cancer cells growth, causes G0/G1 phase arrest and induces apoptotic cell death, and such effects can be reversed by PPARγ antagonist. 4-O-Methyl honokiol inhibits NF-κB activity and cancer cell growth, but such effects as well as its activation of PPARγ can be abolished by knock-down of p21 [1] . 4-O-methylhonokiol (0.5, 1 and 2 μM) reduces LPS-induced release of NO, PGE2, ROS, TNF-α and IL-1β in cultured astrocytes, and amyloidogenesis in cultured astrocytes and microglial BV-2 cells [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
4-O-Methyl honokiol (40 or 80 mg/kg, i.p. everyday for 4 weeks) inhibits the growth of SW620 and PC3 tumours in SW620 and PC3 xenograft model. 4-O-Methyl honokiol significantly increases the expression of p21 and PPARγ in the tumour tissues [1] . 4-O-Methyl honokiol (0.5 or 1 mg/kg/day daily for 3 weeks) significantly ameliorates LPS-induced memory impairment, and inhibits LPS-induced iNOS and COX-2 expression in mice. 4-O-Methyl honokiol also shows inhibitory activities against the Aβ 1-42 accumulation, and activates astrocytes and microglia in LPS-injected mice brain [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Viscous liquid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Pure form | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 356.68 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.5668 mL | 17.8342 mL | 35.6684 mL |
| 5 mM | 0.7134 mL | 3.5668 mL | 7.1337 mL |
| 10 mM | 0.3567 mL | 1.7834 mL | 3.5668 mL |
References
- [1] Lee NJ, et al. 4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21-mediated suppression of NF-κB activity. Br J Pharmacol. 2013 Mar;168(5):1133-45.
- [2] Lee YJ, et al. Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflammation. 2012 Feb 19;9:35.
Synonyms
